RT Journal Article
T1 Bone loss induced by cancer treatments in breast and prostate cancer patients.
A1 Castañeda, Santos
A1 Casas, Ana
A1 González-Del-Alba, Aránzazu
A1 Martínez-Díaz-Guerra, Guillermo
A1 Nogués, Xavier
A1 Ojeda Thies, Cristina
A1 Torregrosa Suau, Óscar
A1 Rodríguez-Lescure, Álvaro
K1 Antiresorptive agents
K1 Bone health
K1 Bone turnover marker
K1 Cancer
K1 Diagnosis
K1 Fragility fracture
K1 Hormone deprivation therapy
K1 Hormone therapy
K1 Osteoporosis
AB Cancer and cancer therapies are a major factor risk for osteoporosis due to bone loss and deterioration of bone microarchitecture. Both factors contribute to a decrease in bone strength and, consequently, increased bone fragility and risk of fracture. Cancer-associated bone loss is a multifactorial process, and optimal interdisciplinary management of skeletal health, accurate assessment of bone density, and early diagnosis are essential when making decisions aimed at reducing bone loss and fracture risk in patients who have received or are receiving treatment for cancer. In this document, a multidisciplinary group of experts collected the latest evidence on the pathophysiology of osteoporosis and its prevention, diagnosis, and treatment with the support of the Spanish scientific society SEOM. The aim was to provide an up-to-date and in-depth view of osteoporotic risk and its consequences, and to present a series of recommendations aimed at optimizing the management of bone health in the context of cancer.
YR 2022
FD 2022-07-02
LK http://hdl.handle.net/10668/21186
UL http://hdl.handle.net/10668/21186
LA en
DS RISalud
RD Apr 7, 2025